Tezepelumab — Membership Pricing
Tezepelumab is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Tezepelumab Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $55.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Tezepelumab
Tezepelumab is a prescription medication. Ask your doctor if Tezepelumab is right for you.
How to Check Tezepelumab Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Tezepelumab at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Respiratory & Allergies
What Tezepelumab is approved for (FDA label)
TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 ) • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) 1.1 Asthma TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Source: Read the full FDA label on DailyMed. Label effective date: October 17, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Tezepelumab (FDA label)
Injection: a clear to opalescent, colorless to light yellow solution available as: • 210 mg/1.91 mL (110 mg/mL) solution in a single-dose glass vial. • 210 mg/1.91 mL (110 mg/mL) solution in a single-dose pre-filled syringe. • 210 mg/1.91 mL (110 mg/mL) solution in a single‑dose pre‑filled pen. Injection: • 210 mg/1.91 mL (110 mg/mL) solution in a single-dose glass vial. ( 3 ) • 210 mg/1.91 mL (110 mg/mL) solution in a single-dose pre-filled syringe. ( 3 ) • 210 mg/1.91 mL (110 mg/mL) solution in a single‑dose pre‑filled pen. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 60f0aa03-ad25-4d48-80ce-7fcfa76f325f. SPL document ID: 4eca89a7-2254-4ee1-9662-c7a84ef7c4b9. Label effective date: October 17, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Tezepelumab (FDA label)
The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Most common adverse reactions (incidence ≥ 3%) are: • Asthma: pharyngitis, arthralgia, and back pain. ( 6.1 ) • Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 60f0aa03-ad25-4d48-80ce-7fcfa76f325f. SPL document ID: 4eca89a7-2254-4ee1-9662-c7a84ef7c4b9. Label effective date: October 17, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Tezepelumab (FDA label)
TEZSPIRE is contraindicated in patients who have known hypersensitivity to tezepelumab-ekko or any of its excipients [see Warnings and Precautions (5.1) ] . Known hypersensitivity to tezepelumab-ekko or excipients. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 60f0aa03-ad25-4d48-80ce-7fcfa76f325f. SPL document ID: 4eca89a7-2254-4ee1-9662-c7a84ef7c4b9. Label effective date: October 17, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Tezepelumab (FDA label)
• Hypersensitivity Reactions: Hypersensitivity reactions have been observed in the clinical trials (e.g., rash, allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported.
Source: FDA prescribing information (DailyMed). Set ID: 60f0aa03-ad25-4d48-80ce-7fcfa76f325f. SPL document ID: 4eca89a7-2254-4ee1-9662-c7a84ef7c4b9. Label effective date: October 17, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Tezepelumab (FDA label)
No formal drug interaction studies have been performed with TEZSPIRE.
Source: FDA prescribing information (DailyMed). Set ID: 60f0aa03-ad25-4d48-80ce-7fcfa76f325f. SPL document ID: 4eca89a7-2254-4ee1-9662-c7a84ef7c4b9. Label effective date: October 17, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.